Shuoyang Zhang, Qian Qiu, Shan Zeng, Hao Li, Liujing Xu, Ligang Jie, Xuejun Hu, Youjun Xiao, Dongying Chen, Zhongping Zhan, Liuqin Liang, Qinghong Yu, Hanshi Xu
Clinical rheumatology 2024 JanBelimumab is a biological agent approved for the treatment of active lupus nephritis (LN), but its efficacy on refractory lupus nephritis (LN) is unknown. This study aims to evaluate the efficacy and safety of belimumab in Chinese patients with refractory LN. This multicenter, observational, and retrospective study enrolled patients with refractory LN who failed induction therapy with steroids, cyclophosphamide, mycophenolate, and calcineurin inhibitors and received 24-week belimumab treatment before data analysis. Treatment outcomes include the overall clinical response (physician judgment, disease activity, organ damage) and renal response (complete renal response, partial renal response, no renal response). Laboratory indices and adverse events were recorded as well. Of the 45 patients enrolled in the study, 6 (13.3%) achieved complete renal response, 19 (42.2%) achieved partial renal response, and the overall renal response rate was 55.6%. Median rSLEDAI decreased from 12 (IQR 8-12) at baseline to 8 (IQR 4-8) (p < 0.0001), 4 (IQR 4-8) (p < 0.0001) at 12 and 24 weeks. Mean urinary protein decreased more than 50% from 3.2 g/24 h at baseline to 1.0 g/24 h at 24 weeks (p < 0.0001). The conditions of hypoalbuminemia and hypocomplementemia had also gradually improved. The levels of autoantibodies showed a significant downward trend. Additionally, 9 (20.0%) patients successfully reduced the dosage of prednisone to a safe range, and 3 of them achieved their treatment goal of prednisone cessation. The mean prednisone dosage decreased from 32.7 mg/day at baseline to 18.6 mg/day (p < 0.0001), 13.3 mg/day (p < 0.0001) at 12 and 24 weeks. There were 3 adverse events reported, including 2 cases of infection, and 1 case of allergy. No serious events occurred during the follow-up. Belimumab is effective and safe when used in clinical practice, which can be considered as an add-on therapy for refractory LN. Key Points • A multicenter observational study in the real clinical settings of China. • First revealed the efficacy and safety of belimumab in Chinese patients with refractory LN. © 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Shuoyang Zhang, Qian Qiu, Shan Zeng, Hao Li, Liujing Xu, Ligang Jie, Xuejun Hu, Youjun Xiao, Dongying Chen, Zhongping Zhan, Liuqin Liang, Qinghong Yu, Hanshi Xu. Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study. Clinical rheumatology. 2024 Jan;43(1):199-208
PMID: 37982925
View Full Text